Trustees’ Annual Report 2025

UK Acute Oncology Society (UKAOS)

Charity registration number: 1199351
Legal form: Charitable Incorporated Organisation (CIO)
Reporting period: [insert start date] to [insert end date]
Gross income: Less than £25,000

Principal office: UKAOS Secretariat, c/o Media1 Productions Ltd, Clarence Mill, Clarence Road, Bollington, Macclesfield SK10 5JZ

Reference and administrative details

Trustees who served during the reporting period:

- Ernest Marshall Chair
- Joanne Upton Trustee
- Donna Munro Trustee
- Philippa Jacqueline Jones Trustee
- Dr Hilary Williams Trustee
- Dr Caroline Wilson Trustee

Structure, governance and management

UKAOS is a Charitable Incorporated Organisation governed by its constitution dated 16 June 2022 and updated on 18 January 2025. The Board of Trustees is responsible for the charity’s strategic direction, financial stewardship, legal compliance and oversight of risk.

Trustee appointment, induction and organisation

Trustees are appointed in accordance with the constitution, having regard to the skills, experience and diversity of perspective required by the Board. New trustees receive appropriate induction on the charity’s purposes, governing document, trustee duties, finances and current priorities.

How the charity is managed

- Board of Trustees: The governing body responsible for the overall strategic direction, financial oversight, and legal compliance of the charity.
- Operational Steering Group: Oversight of Operational delivery of the work plan and strategy

- Programme Management Group: Responsibility for cross cutting themes and governance policy development.
- Sub-groups with defined scope and terms of reference.

Objectives and activities

Charitable purposes

- For the public benefit to advance the education of all healthcare professionals involved in treating or supporting patients in the field of acute oncology
- In furtherance of the object above, to promote research for the public benefit in all aspects of that subject and to publish the useful results
- The relief of sickness and preservation of health, from cancer.
- To assist in the treatment and care of persons suffering from cancer, or in need of rehabilitation, by the provision of education for healthcare professionals
- To promote the wellbeing of people suffering from acute effects of cancer and/or anti-cancer treatment and support the development of acute oncology services

Public benefit

The trustees have had due regard to the Charity Commission's guidance on public benefit when planning and delivering the charity's work.

UKAOS advances education for healthcare professionals involved in acute oncology, promotes research and dissemination of useful findings, and supports improvements in the treatment, care and wellbeing of people affected by cancer and the acute effects of cancer treatment.

During the year, the charity delivered public benefit through:

- **Education:** conferences, online learning and professional events designed to improve the quality and safety of urgent cancer care.
- **Service improvement:** development and publication of practical pathways, reviews and guidance for acute oncology services.
- **Research, data and policy:** collaboration with national partners to strengthen evidence, data quality and the voice of acute oncology in national cancer policy.

Achievements and performance

The charity's principal achievements during the year are summarised under six strategic themes.

1. **Publications and guidance.** Published the first five-year UKAOS strategy; launched a four-nation review of 24/7 systemic anti-cancer therapy helplines; published initial Same Day Emergency Care pathways for unexpected pulmonary embolism, metastatic spinal cord compression and low-risk febrile neutropenia; and progressed reviews of malignancy of unknown origin services and acute oncology in emergency departments.
2. **Education.** Delivered the UKAOS annual conference and established the online Learning Hour programme, alongside contributions to national oncology and systemic anti-cancer therapy events.
3. **Urgent cancer care data.** Continued work to improve reporting through the Cancer Outcomes and Services Dataset and CancerStats2, and secured a national partnership with Macmillan Cancer Support and the National Disease Registration Service to investigate urgent-care use among people with lung cancer receiving systemic anti-cancer therapy.
4. **Governance and policy.** Completed a governance review, established an Operational Steering Group and continued to develop policies and procedures to support effective oversight.
5. **Income generation.** Explored fundraising opportunities to strengthen the charity's education and service-improvement work.
6. **National policy.** Supported the inclusion of a commitment to develop acute and supportive oncology quality standards within national cancer policy.

Financial review

The charity's gross income for the reporting period was less than £25,000. Full details of receipts, payments, assets and liabilities are set out in the annual accounts approved by the trustees.

Reserves: The charity did not have a formally approved reserves policy at the reporting date. The trustees will develop and approve an appropriate policy during 2026, taking account of planned commitments, financial risks and the need for operational continuity.

Going concern: Having reviewed available funds and anticipated commitments, the trustees consider that the charity has adequate resources to continue its activities for the foreseeable future, subject to confirmation when approving the accounts.

Debts and custodian funds: “The charity had no material debts and held no funds as custodian trustee at the year end.”]

Risk management and trustee responsibilities

The trustees regularly consider the principal risks facing the charity and take proportionate steps to manage them. These include financial sustainability, governance capacity, data protection, reputation and delivery of activities through partners or volunteers.

The trustees are responsible for maintaining proper accounting records, safeguarding the charity’s assets, preparing annual accounts and a trustees’ annual report, and ensuring that the charity acts in accordance with its constitution and applicable law.

Serious incidents: No serious incidents requiring a report to the Charity Commission were identified

Plans for the next reporting period

- Continue delivery of accessible education for acute oncology professionals.
- Complete and disseminate further service reviews, pathways and guidance.
- Strengthen partnerships supporting urgent cancer care data and research.
- Embed the revised governance framework and complete the next phase of policy development.
- Approve a proportionate reserves policy and pursue sustainable income opportunities.

Approval and declaration

This report was approved by the Board of Trustees on [insert date] and signed on its behalf by:

Ernest Marshall, Chair

Signature: ________

Date: _____02/09/2026_____

2025

⚖ CHARITY COMMISSION FOR ENGLAND AND WALES	Charity Name
	UK Acute Oncology Society (UKAOS)

For the period from	Period start date 1-Jan-25

Section A Receipts and payments

	Unrestricted funds to the nearest £	**Restricted funds to the nearest £**
A1 Receipts		
Sponsorships and grants	25,000	
Sub total (Gross income for AR)	**25,000**	**-**
Funds received in error	0	
Sub total	**0**	**-**
Total receipts	**25,000**	
A3 Payments		
Bank charges	240	
Website expenses	1473	
Secretariat	6,708	
Accountancy	924	
Repayment for funds received in error	0	
Sub total	**9,345**	**-**

Sub total		**-**
Total payments	**9,345**	**-**
Net of receipts/(payments)	**15,655**	**-**
A5 Transfers between funds	4,755	
A6 Cash funds last year end	**20,410**	**-**

	Categories	Details
B1	**Cash funds**	Bank

		Details
B2	**Other monetary assets**	

		Details
B3	**Investment assets**	

B4 **Assets retained for the charity's own use**

Details

B5 **Liabilities**

Details

Signed by one or two trustees on behalf of all the trustees

Signa

	No (if any) 1199351

Receipts and payments accounts

To	Period end date 31-Dec-25	

Endowment funds to the nearest £	**Total funds to the nearest £**	**Last year to the nearest £**
	25,000	14,000
	-	
	-	
	-	
	-	
-	**25,000**	**14,000**
	0	4,800
-	**0**	**4,800**
	25,000	**18,800**
	240	265
	1473	848
	6708	21,306
	924	900
		10,800
-	**9,345**	**34,119**
	-	

-	-	-
-	**9,345**	**34,119**
-	**15,655**	**-15,319**
	4,755	20,074
-	**20,410**	**4,755**

	Unrestricted funds to nearest £	Restricted funds to nearest £
	20,410	
Total cash funds	**20,410**	**-**
(agree balances with receipts and payments account(s))	**OK**	**OK**

	Unrestricted funds to nearest £	Restricted funds to nearest £

	Fund to which asset belongs	Cost (optional)

	Fund to which asset belongs	Cost (optional)

	Fund to which liability relates	Amount due (optional)

ature

Print Name

	E MARSHALL

###

CHARITY COMMISSION FOR ENGLAND AND WALES

Charity Name: UK Acute Oncol

Recei

For the period from

Section A Receipts and payments

	Unrestricted funds to the nearest £
A1 Receipts	
Sponsorships and grants	14,000
	-
	-
	-
	-
	-
	-
	-
Sub total *(Gross income for AR)*	14,000
Funds received in error	4,800
	-
Sub total	4,800
Total receipts	18,800
A3 Payments	
Bank charges	265
Website expenses	848
Secretariat	21,306
Accountancy	900
Repayment for funds received in error	10,800
	-
	-
	-
	-
Sub total	34,119
A4 Asset and investment purchases, (see table)	
	-
	-
Sub total	-
Total payments	34,119
Net of receipts/(payments)	- 15,319
A5 Transfers between funds	-
A6 Cash funds last year end	20,074
Cash funds this year end	4,755

Section B Statement of assets and li

Categories	Details
B1 Cash funds	Bank
	Tota
	(agree balances with re

	Details
B2 Other monetary assets	

-15,319 0

B3 Investment assets

Details

B4 Assets retained for the charity's own use

Details

B5 Liabilities

Details

Signed by one or two trustees on behalf of all the trustees

Signatur

CCXX R2 accounts (SS)

Endowment funds to nearest £

-

OK

Endowment funds to nearest £

Current value (optional)

Current value

(optional)

When due

(optional)

Date of

approval

9/18/2026

9/18/2026

ogy Society (UKAOS)	No (if any) 1199351	CC16a

ipts and payments accounts

Period start date	To	Period end date
01-Jan-24		31-Dec-24

Restricted funds to the nearest £	Endowment funds to the nearest £	Total funds to the nearest £	Last year to the nearest £
-	-	14,000	20,000
-	-	-	-
-	-	-	-
-	-	-	-
-	-	-	-
-	-	-	-
-	-	-	-
-	-	-	-
-	-	14,000	20,000
-	-	4,800	6,000
-	-	-	-
-	-	4,800	6,000
-	-	18,800	26,000
-	-	265	300
-	-	848	2,058
-	-	21,306	7,162
-	-	900	900
-	-	10,800	-
-	-	-	-
-	-	-	-
-	-	-	-
-	-	-	-
-	-	34,119	10,420
-	-	-	
-	-	-	
-	-	-	-
-	-	34,119	10,420
-	-	- 15,319	15,580
-	-	-	-
-	-	20,074	4,494
-	-	4,755	20,074

abilities at the end of the period

	Unrestricted funds to nearest £	Restricted funds to nearest £	Endowment funds to nearest £
	4,755	-	-
	-	-	-
	-	-	-
l cash funds	4,755	-	-
ceipts and payments account(s))	OK	OK	OK

	Unrestricted funds to nearest £	Restricted funds to nearest £	Endowment funds to nearest £
	-	-	-

	-	-	-
	-	-	-
	-	-	-
	-	-	-
	-	-	-

	Fund to which asset belongs	Cost (optional)	Current value (optional)
		-	-
		-	-
		-	-
		-	-
		-	-

	Fund to which asset belongs	Cost (optional)	Current value (optional)
		-	-
		-	-
		-	-
		-	-
		-	-
		-	-
		-	-
		-	-
		-	-

	Fund to which liability relates	Amount due (optional)	When due (optional)
		-	
		-	
		-	
		-	

e	Print Name	Date of approval
	E MARSHALL	24/10/2025

2025 Incor

Income and Expenditure Account UK Acute Oncol

Income from Donations

Date	Category
1/28/2025	Income
4/24/2025	Income
8/1/2025	Income
12/19/2025	Income
12/22/2025	Income
Total Result	

Expenditure from Donations

cleaned narrative	Date
Outward Faster Payment – Media 1 productions	12/16/2025
Account to Account Transfer – SAWIN & EDWARDS LLP	11/6/2025
Outward Faster Payment – Frank Design Ltd	11/6/2025
Online Banking Monthly Fee	1/31/2025
	2/28/2025
	3/28/2025
	4/28/2025
	5/28/2025
	6/27/2025
	7/28/2025
	8/28/2025
	9/26/2025
	10/28/2025
	11/28/2025
	12/24/2025
Total Result	

ne and Expenditure Account

ogy Society (UKAOS)

cleaned narrative	Sum of Mone
Inward Payment – GILEAD SCIENCES LTD (ref: 012/11.12.2024)	4000
BACS Payment Received – DAIICHI (0150000359)	4000
Inward Payment – CAREOLOGY HEALTH LIMITED	500
BACS Payment Received – BIOMERIEUX UK LTD (00072000318198)	12500
BACS Payment Received – ASTRAZENECA UK LIM (INV/106625779)	4000
	25000

Category	Sum of Mone
Secretariate	6708
Audit Costs	1473
WebSite	924
Bank Fees	20
Bank Fees	20
Bank Fees	20
Bank Fees	20
Bank Fees	20
Bank Fees	20
Bank Fees	20
Bank Fees	20
Bank Fees	20
Bank Fees	20
Bank Fees	20
Bank Fees	20
	9345

Opening Bank Balance (1/1/25)	**4755.4**	
Income	25000	
ey In (£) Expenditure	9345	
Closing Bank Balance	**20410.4**	

Metro Bank Communit
BIC: MYMBGB2L IBAN: GB78MY

UK ACUTE ONCOLOGY SOCIETY
PARKSHOT HOUSE 5 KEW ROAD
RICHMOND
TW9 2PR

Metro Bank Community Account Statement

BIC: MYMBGB2L IBAN: GB78MYMB23058045767981

METRO BANK

One Southampton Row
London WC1B 5HA
T: 0345 08 08 500
metrobankonline.co.uk

UK ACUTE ONCOLOGY SOCIETY (UKAOS)
PARKSHOT HOUSE 5 KEW ROAD
RICHMOND
TW9 2PR

ACCOUNT NAME: UK ACUTE ONCOLOGY SOCIETY (UKAOS)

Your account summary

From: 01 JAN 2026	To:	31 JAN 2026
Opening balance		£20,410.40
Total money in		£4,000.00
Total money out		£23.00
End balance		£24,387.40

Account number	45767981
Sort code	23-05-80
Statement number	43
Overdraft limit	£0.00

Your transactions

Date	Transaction	Money out (£)	Money in (£)	Balance (£)
	Balance brought forward			20,410.40
16 JAN 2026	BACS Payment Received BRISTOL 020 UKAOS UK ACUTE ONC		4,000.00	24,410.40
28 JAN 2026	Account Maintenance Fee	3.00		24,407.40
28 JAN 2026	Online Banking Mthly Fee	20.00		24,387.40
	Closing Balance			24,387.40

Metro Bank PLC is registered in England and Wales, company number 8419670. Registered office: One Southampton Row, London WC1B 5HA. Authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and Prudential Regulation Authority. Metro Bank is the registered trade mark of Metro Bank PLC.

Your account summar

From: 01 JAN 2025	To:
Opening balance	
Total money in	
Total money out	
End balance	

Your transactions

Date	Transaction
	Balance brought
09 JAN 2025	Inward Payment 1/GILEAD SCIENC
	012/11.12.2024
28 JAN 2025	Online Banking Mt
	Closing Balance

ey Out (£)

ty Account Statement

MB23058045767981

One Southampton Row
London WC1B 5HA
T: 0345 08 08 500
metrobankonline.co.uk

r (UKAOS)
)

ACCOUNT NAME: UK ACUTE ONCOLOGY SOCIETY (UKAOS)

ry

31 JAN 2025
£4,755.40
£4,000.00
£20.00
£8,735.40

Account number	45767981
Sort code	23-05-80
Statement number	31
Overdraft limit	£0.00

	Money out (£)	Money in (£)	Balance (£)
forward			**4,755.40**
		4,000.00	8,755.40
ES LTD			
hly Fee	20.00		8,735.40
			8,735.40

Source: Bar

Date
1/31/2025
2/28/2025
3/28/2025
4/28/2025
5/28/2025
6/27/2025
7/28/2025
8/28/2025
9/26/2025
10/28/2025
11/28/2025
12/24/2025
1/28/2025
4/24/2025
8/1/2025
12/19/2025
12/22/2025
11/6/2025
11/6/2025
12/16/2025

ıak Statements

Description
Online Banking Monthly Fee [eu-prod.as...rosoft.com]
Online Banking Monthly Fee [eu-prod.as...rosoft.com]
Online Banking Monthly Fee [statement-...25-January | PDF]
Online Banking Monthly Fee [statement-...5-February | PDF]
Online Banking Monthly Fee [statement-2025-March | PDF]
Online Banking Monthly Fee [statement-2025-April | PDF]
Online Banking Monthly Fee [statement-2025-May | PDF]
Online Banking Monthly Fee [statement-2025-June | PDF]
Online Banking Monthly Fee [statement-2025-July | PDF]
Online Banking Monthly Fee [statement-...025-August | PDF]
Online Banking Monthly Fee [statement-...-September | PDF]
Online Banking Monthly Fee [statement-...25-October | PDF]
Inward Payment – GILEAD SCIENCES LTD (ref: 012/11.12.2024) [eu-prod.as...rosoft.com]
BACS Payment Received – DAIICHI (0150000359) [statement-...5-February | PDF]
Inward Payment – CAREOLOGY HEALTH LIMITED [statement-2025-June | PDF]
BACS Payment Received – BIOMERIEUX UK LTD (00072000318198) [statement-...25-October | PDF]
BACS Payment Received – ASTRAZENECA UK LIM (INV/106625779) [statement-...25-October | PDF]
Account to Account Transfer – SAWIN & EDWARDS LLP (UKAOS) [statement-...-September | PDF]
Outward Faster Payment – Frank Design Ltd [statement-...-September | PDF]
Outward Faster Payment – Media 1 productions [statement-...25-October | PDF]

Money In (£)	Money Out (£)	Balance After (£)	Category
0	20	8735.4	Bank Fees
0	20	8715.4	Bank Fees
0	20	8695.4	Bank Fees
0	20	12675.4	Bank Fees
0	20	12655.4	Bank Fees
0	20	12635.4	Bank Fees
0	20	12615.4	Bank Fees
0	20	13095.4	Bank Fees
0	20	13075.4	Bank Fees
0	20	13055.4	Bank Fees
0	20	10638.4	Bank Fees
0	20	20410.4	Bank Fees
4000	0	8755.4	Income
4000	0	12695.4	Income
500	0	13115.4	Income
12500	0	16430.4	Income
4000	0	20430.4	Income
0	1473	10658.4	Audit Costs
0	924	12131.4	WebSite
0	6708	3930.4	Secretariate

cleaned narrative
Online Banking Monthly Fee
Online Banking Monthly Fee
Online Banking Monthly Fee
Online Banking Monthly Fee
Online Banking Monthly Fee
Online Banking Monthly Fee
Online Banking Monthly Fee
Online Banking Monthly Fee
Online Banking Monthly Fee
Online Banking Monthly Fee
Online Banking Monthly Fee
Online Banking Monthly Fee
Online Banking Monthly Fee
Inward Payment – GILEAD SCIENCES LTD (ref: 012/11.12.2024)
BACS Payment Received – DAIICHI (0150000359)
Inward Payment – CAREOLOGY HEALTH LIMITED
BACS Payment Received – BIOMERIEUX UK LTD (00072000318198)
BACS Payment Received – ASTRAZENECA UK LIM (INV/106625779)
Account to Account Transfer – SAWIN & EDWARDS LLP (UKAOS)
Outward Faster Payment – Frank Design Ltd
Outward Faster Payment – Media 1 productions